Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.76 |
| ▸ | BRD2 | P25440 | 17/20 | 0.76 |
| ▸ | BRD3 | Q15059 | 17/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740758 | 0.87 | BRD4 (1.00) | BRD4BRD2BRD3 | |
| SCHEMBL14740769 | 0.87 | BRD4 (0.74) | BRD4BRD2BRD3 | |
| SCHEMBL15980898 | 0.85 | BRD4 (0.72) | BRD4BRD2BRD3 | |
| SCHEMBL15980799 | 0.84 | BRD4 (0.76) | BRD4BRD2BRD3 | |
| SCHEMBL14756139 | 0.81 | BRD4 (0.71) | BRD4BRD2BRD3 | |
| SCHEMBL14756377 | 0.79 | BRD4 (0.85) | BRD4BRD2BRD3 | |
| SCHEMBL14756381 | 0.79 | BRD4 (0.85) | BRD4BRD2BRD3 | |
| SCHEMBL15984849 | 0.79 | BRD4 (1.00) | BRD4BRD2BRD3 | |
| SCHEMBL15782904 | 0.79 | BRD4 (0.62) | BRD4BRD2BRD3 | |
| SCHEMBL12338501 | 0.78 | BRD4 (0.63) | BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | BRD4 3/4885BRD2 2/4885BRD3 4/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 5/4885BRD3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.